Perspective Therapeutics/$CATX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Perspective Therapeutics
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Ticker
$CATX
Sector
Primary listing
AMEX
Industry
Biotechnology
Headquarters
Employees
139
ISIN
US46489V3024
CATX Metrics
BasicAdvanced
$281M
-
-$1.21
1.13
-
Price and volume
Market cap
$281M
Beta
1.13
52-week high
$16.55
52-week low
$1.60
Average daily volume
1.5M
Financial strength
Current ratio
17.016
Quick ratio
16.703
Long term debt to equity
0.978
Total debt to equity
1.341
Interest coverage (TTM)
-514.45%
Profitability
EBITDA (TTM)
-72.949
Gross margin (TTM)
-3,005.03%
Net profit margin (TTM)
-5,790.07%
Operating margin (TTM)
-5,140.99%
Effective tax rate (TTM)
2.42%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-15.56%
Return on equity (TTM)
-32.92%
Valuation
Price to revenue (TTM)
180.232
Price to book
0.98
Price to tangible book (TTM)
1.19
Price to free cash flow (TTM)
-2.556
Free cash flow yield (TTM)
-39.12%
Free cash flow per share (TTM)
-147.89%
Growth
Revenue change (TTM)
-3.60%
Earnings per share change (TTM)
-30.52%
What the Analysts think about CATX
Analyst ratings (Buy, Hold, Sell) for Perspective Therapeutics stock.
CATX Financial Performance
Revenues and expenses
CATX Earnings Performance
Company profitability
CATX News
AllArticlesVideos
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting
GlobeNewsWire·3 weeks ago
![Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fg%2Fw%2Fc%2Fpress3-3148314.jpg&w=3840&q=75)
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial
GlobeNewsWire·3 weeks ago
![Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting](/_next/image?url=https%3A%2F%2Fcdn.snapi.dev%2Fimages%2Fv1%2Fa%2Fg%2Fj%2Fpress19-3115929.jpg&w=3840&q=75)
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Perspective Therapeutics stock?
Perspective Therapeutics (CATX) has a market cap of $281M as of July 10, 2025.
What is the P/E ratio for Perspective Therapeutics stock?
The price to earnings (P/E) ratio for Perspective Therapeutics (CATX) stock is 0 as of July 10, 2025.
Does Perspective Therapeutics stock pay dividends?
No, Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Perspective Therapeutics dividend payment date?
Perspective Therapeutics (CATX) stock does not pay dividends to its shareholders.
What is the beta indicator for Perspective Therapeutics?
Perspective Therapeutics (CATX) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.